UNIVERSITY OF UTAH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1850-02-28
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.utah.edu
Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
Phase 2
Withdrawn
- Conditions
- Glioblastoma Multiforme (GBM)
- Interventions
- Drug: Fluciclitite , PET imaging, and Bevacizumab
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- University of Utah
- Registration Number
- NCT01788280
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
VA Integrated Medication Manager
Not Applicable
Completed
- Conditions
- Electronic Health Records
- Interventions
- Other: Integrated Medication Manager
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 58
- Registration Number
- NCT01787175
- Locations
- 🇺🇸
VA SLC Health Care System, Salt Lake City, Utah, United States
Immunization Protection in Child Care (IPiCC) Project
Not Applicable
Completed
- Conditions
- Up-to-date Immunization Status for Children in Child Care
- Interventions
- Behavioral: Intervention child care programs
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 107
- Registration Number
- NCT01773759
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Hip Strength and Nerve Palsy After the Modified Stoppa Approach to Acetabular Fracture Reduction and Fixation
Terminated
- Conditions
- Pelvic FractureAcetabular Fracture
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 43
- Registration Number
- NCT01763359
- Locations
- 🇺🇸
University of Utah Orthopedics Center, Salt Lake City, Utah, United States
Functional Implications of Arthroscopic Iliopsoas Release
Completed
- Conditions
- Arthroscopic Iliopsoas Release
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 36
- Registration Number
- NCT01763372
Laparoscopic Versus Open Appendectomy? Let the Patient Decide
Not Applicable
Completed
- Conditions
- Appendicitis
- Interventions
- Other: Cost Information Included
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 100
- Registration Number
- NCT01738750
- Locations
- 🇺🇸
Primary Children's Hospital, Salt Lake City, Utah, United States
Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant
Completed
- Conditions
- Bone Marrow Transplant
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 23
- Registration Number
- NCT01735565
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Primary Children's Medical Center, Salt Lake City, Utah, United States
Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis
Completed
- Conditions
- Anemia of PrematurityNecrotizing Enterocolitis
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 52
- Registration Number
- NCT01735578
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates
Terminated
- Conditions
- Anemia of PrematurityNecrotizing Enterocolitis
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 12
- Registration Number
- NCT01735552
- Locations
- 🇺🇸
Intermountain Medical Center, Murray, Utah, United States
🇺🇸Primary Children's Medical Center, Salt Lake City, Utah, United States
🇺🇸University of Utah Hospital, Salt Lake City, Utah, United States
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung CancerStage IV DiseaseEGFR Unknown or Wild-type
- Interventions
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- University of Utah
- Registration Number
- NCT01728181
© Copyright 2025. All Rights Reserved by MedPath